- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Greenwich LifeSciences files patent claims for breast cancer therapy | 1 | Investing.com | ||
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential | 194 | GlobeNewswire (Europe) | STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 31.03. | Greenwich LifeSciences, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 19.03. | Greenwich LifeSciences: Phase-III-Studie wird auf City of Hope-Standorte ausgeweitet | 3 | Investing.com Deutsch | ||
| 19.03. | Greenwich LifeSciences expands Phase III trial to City of Hope sites | 1 | Investing.com | ||
| 19.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 | 3 | GlobeNewswire (USA) | ||
| 18.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Upcoming AACR Meeting | 1 | GlobeNewswire (USA) | ||
| 18.03. | Greenwich LifeSciences to present trial data at AACR meeting | 1 | Investing.com | ||
| 17.03. | Greenwich LifeSciences reports reduced cancer recurrence in trial | 14 | Investing.com | ||
| 17.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 | 190 | GlobeNewswire (Europe) | STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 16.03. | Greenwich LifeSciences begins using commercial GP2 at US sites | 1 | Investing.com | ||
| 16.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 | 141 | GlobeNewswire (Europe) | STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 03.03. | Greenwich LifeSciences reports 33% rise in trial screening rate | 2 | Investing.com | ||
| 03.03. | Greenwich LifeSciences: Screening-Rate für Brustkrebsstudie steigt um 33 % | 1 | Investing.com Deutsch | ||
| 03.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 | 634 | GlobeNewswire (Europe) | STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 24.02. | Greenwich LifeSciences abstracts accepted at AACR 2026 meeting | 2 | Investing.com | ||
| 24.02. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 27.01. | Greenwich LifeSciences reports $12.5 million cash balance | 2 | Investing.com | ||
| 27.01. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy | 195 | GlobeNewswire (Europe) | STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 26.01. | Greenwich LifeSciences-Aktie: Wird sie zum Impfstoff-Überflieger? | 351 | sharedeals.de | Die Aktie von Greenwich LifeSciences sorgte kürzlich mit einem Unternehmensupdate für neue Aufmerksamkeit. Ausschlaggebend ist weniger ein klinischer Meilenstein als vielmehr ein regulatorischer Fortschritt... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| KUROS BIOSCIENCES | 26,460 | +0,38 % | Kuros schreibt 2025 schwarze Zahlen | Schlieren - Das Biotechunternehmen Kuros hat Wort gehalten und den Umsatz 2025 um mehr als 70 Prozent gesteigert. Getragen wurde die Entwicklung erneut durch das Knochenersatzprodukt MagnetOs. Konkret... ► Artikel lesen | |
| ABIVAX | 106,40 | -0,75 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,409 | +4,91 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,140 | -0,48 % | Jefferies reiterates Iovance Biotherapeutics stock rating at buy | ||
| DENALI THERAPEUTICS | 16,305 | -0,55 % | Takeda tears up Denali partnership, returning dementia asset amid restructuring | ||
| ARGENX | 681,20 | -0,21 % | UBS stuft Argenx auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Argenx auf "Neutral" mit einem Kursziel von 850 US-Dollar belassen. Die Quartalszahlen des Biotech-Spezialisten am 7. Mai dürften angesichts... ► Artikel lesen | |
| CAPRICOR | 26,140 | -1,73 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| INSMED | 131,50 | -0,41 % | Insmed Incorporated: Insmed Provides Clinical Update on Phase 2b CEDAR Study | -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program-
-Safety Was Consistent with Previous Studies and No New Safety... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,160 | +0,99 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| REVOLUTION MEDICINES | 82,40 | +0,24 % | Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress | On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 21,440 | +2,83 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 - - Revuforj- (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 - - Niktimvo... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 13,100 | +1,91 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst |
Das Unternehmen GREENWICH LIFESCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,12 % bei einem Aktienkurs von 25,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.